Items where authors include "Camu, W."

Article

Bensimon, G., Leigh, P.N., Tree, T. et al. (50 more authors) (2025) Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial. The Lancet, 405 (10492). pp. 1837-1850. ISSN 0140-6736

Saez-Atienzar, S., Souza, C.D.S., Chia, R. et al. (323 more authors) (2024) Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data. Cell Genomics, 4 (11). 100679. ISSN 2666-979X

Alarcan, H. orcid.org/0009-0002-8788-2773, Bruno, C., Emond, P. et al. (20 more authors) (2024) Pharmacometabolomics applied to low‐dose interleukin‐2 treatment in amyotrophic lateral sclerosis. Annals of the New York Academy of Sciences, 1536 (1). pp. 82-91. ISSN 0077-8923

Lombardo, F.L. orcid.org/0000-0001-6183-0735, Spila Alegiani, S., Mayer, F. et al. (93 more authors) (2023) A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Trials, 24 (1). 792. ISSN 1468-6708

Opie-Martin, S., Iacoangeli, A., Topp, S.D. et al. (46 more authors) (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nature Communications, 13 (1). 6901. ISSN 2041-1723

Giovannelli, I., Bayatti, N., Brown, A. et al. (23 more authors) (2021) Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 3 (3). fcab141. ISSN 2632-1297

Dewan, R. orcid.org/0000-0002-7611-7032, Chia, R. orcid.org/0000-0002-4709-7423, Ding, J. et al. (469 more authors) (2021) Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron, 109 (3). 448-460.e4. ISSN 0896-6273

Camu, W., Mickunas, M., Veyrune, J.-L. et al. (18 more authors) (2020) Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 59. 102844. ISSN 2352-3964